TriangleNCT02120157 · OUTCOME
Time to Neutrophil and Platelet Recovery
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- 100 days
What was measured
Time to neutrophil and platelet recovery in median days
Groups in this outcome
Haploidentical BMT With PTCy for Acute Leukemias and MDS
Patients with AML and MDS: Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV For patients with ALL and lymphoblastic lymphoma: Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days All patients Day 0: Infuse unmanipulated bone marrow Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day Day +30: Assess chimerism and disease status in bone marrow Day +35: Discontinue MMF Day +60: Assess chimerism and disease status in bone marrow Day 180: Discontinue tacrolimus Cyclophosphamide: Chemotherapy administration TBI: Radiation Therapy Busulfan: Chemotherapy Administered Unmanipulated Bone Marrow: Bone Marrow Transplant Tacrolimus: Immunosuppressive Drug Administered Mycophenolate mofetil: Immunosuppressive Drug Administered
| Group | Source count |
|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 32 |
Reported measurements
neutrophil
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 22 | Not reported | 14 | 58 | Not reported |
platelet
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 21 | Not reported | 12 | 44 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 14
- upper Limit
- 58
- value
- 22
- title
- neutrophil
- categories
- measurements
- group Id
- OG000
- lower Limit
- 12
- upper Limit
- 44
- value
- 21
- title
- platelet
- denoms
- counts
- group Id
- OG000
- value
- 32
- units
- Participants
- description
- Time to neutrophil and platelet recovery in median days
- dispersion Type
- Full Range
- groups
- description
- Patients with AML and MDS: Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV For patients with ALL and lymphoblastic lymphoma: Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days All patients Day 0: Infuse unmanipulated bone marrow Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day Day +30: Assess chimerism and disease status in bone marrow Day +35: Discontinue MMF Day +60: Assess chimerism and disease status in bone marrow Day 180: Discontinue tacrolimus Cyclophosphamide: Chemotherapy administration TBI: Radiation Therapy Busulfan: Chemotherapy Administered Unmanipulated Bone Marrow: Bone Marrow Transplant Tacrolimus: Immunosuppressive Drug Administered Mycophenolate mofetil: Immunosuppressive Drug Administered
- id
- OG000
- title
- Haploidentical BMT With PTCy for Acute Leukemias and MDS
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 100 days
- title
- Time to Neutrophil and Platelet Recovery
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice